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APLIKASI ANALISIS PELEBURAN RESOLUSI TINGGI DALAM 
PENGESANAN MUTASI GEN PDGFRA DI KALANGAN PESAKIT-
PESAKIT LEUKEMIA MEILOID KRONIK YANG DIRAWAT DENGAN 
IMATINIB MESYLATE 
ABSTRAK 
Pengesanan molekul bagi varian PDGFRA adalah sangat relevan untuk 
meramal prognosis dan terapi untuk pesakit leukemia meiloid kronik (CML) yang 
dirawat dengan Imatinib mesylate (IM). Walaupun IM telah menunjukkan 
keberkesanan dalam rawatan utama CML, namun kemunculan rintangan kepada IM 
telah menjadi masalah utama yang membimbangkan. Kemunculan rintangan 
terhadap IM boleh disebabkan oleh sama ada mekanisma bersandar BCR-ABL atau 
mekanisma tidak bersandar BCR-ABL. Mekanisma tidak bersandar BCR-ABL terdiri 
daripada beberapa faktor termasuk perubahan dalam pharmakokinetik IM seperti 
penyerapan dan pengedaran metabolism. Walau bagaimanapun, kerintangan terhadap 
IM juga boleh berlaku dengan penglibatan tirosina kinase selain daripada BCR-ABL 
yang juga terlibat di dalam kerintangan terhadap IM. Sebagai tindak balas kepada 
permintaan yang semakin meningkat untuk kaedah yang boleh dipercayai, cepat dan 
lebih sensitif, kajian ini menggunakan analisa peleburan resolusi tinggi untuk 
menjelaskan mekanisma yang tidak bersandar BCR-ABL yang melibatkan PDGFRA 
tirosina kinase pada pesakit CML di Malaysia yang menerima rawatan IM. Sejumlah 
86 pesakit CML yang menjalani rawatan IM (43 rintang terhadap IM dan 43 respon 
terhadap IM) telah menyertai kajian ini. Menggunakan analisis peleburan resolusi 
tinggi, 86 pesakit CML telah disaring untuk PDGFRA ekson 10 (c.1432 T>C), ekson 
12 (c.1701 A>G), ekson 14 (c.1977 C>A) and ekson 18 (c.2525 A>T). Sampel yang 
xv 
 
mempunyai corak lengkung lebur yang berbeza daripada sampel rujukan telah 
diteruskan untuk proses penjujukan DNA bagi mengesahkan genotip. Daripada 
analisis data, terdapat dua PDGFRA variasi yang dikenalpasti iaitu PDGFRA ekson 
10 dan 12. Profil HRM yang telah ditubuhkan melalui kajian ini menunjukkan 100% 
sensitiviti dan spesifisiti jika dibandingkan dengan penjujukan DNA. PDGFRA 
ekson 10 menunjukkan faktor risiko yang signifikan untuk pembentukan rintangan 
kepada IM (OR 3.797; 95% CI: 1.502 – 9.591; p = 0.005). PDGFRA ekson 12 pula 
adalah faktor risiko tidak signifikan (OR 1.597; 95% CI: 0.681 – 3.745; p = 0.281) 
untuk kerintangan terhadap IM. Walau bagaimanapun, tiada variasi PDGFRA 
dikesan untuk kedua-dua ekson 14 c.1977 C>G dan ekson 18 c.2525 A>T. 
Keputusan keseluruhan menunjukkan bahawa PDGFRA mempunyai pengaruh dalam 
menentukan kerintangan terhadap IM dalam kalangan pesakit CML dan analisis 
selanjutnya perlu dijalankan untuk mengesahkan peranan PDGFRA dalam 










APPLICATION OF HIGH RESOLUTION MELTING (HRM) ANALYSIS IN 
DETECTION OF PDGFRA GENE MUTATIONS AMONG CHRONIC 
MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB 
MESYLATE 
ABSTRACT 
A molecular detection of PDGFRA variants is highly relevant for prognosis 
and therapy prediction in chronic myeloid leukemia (CML) patients treated with 
Imatinib mesylate (IM). Even though IM has shown an excellent efficacy as a 
frontline treatment in CML, emerging of resistance towards IM in some CML 
patients has become a major concern. The development of resistance can be either 
due to BCR-ABL dependent mechanism or BCR-ABL independent mechanism. The 
BCR-ABL independent mechanisms include factor in pharmacokinetics of IM such as 
absorption and distribution of metabolism. However, resistance to IM can also due to 
the involvement of others IM targeted tyrosine kinases that may play a role in the IM 
resistance. In response to growing demand for reliable, faster and more sensitive 
methods, the present study used a High resolution melting (HRM) analysis to 
elucidate the BCR-ABL independent mechanism involving PDGFRA tyrosine kinase, 
in Malaysian CML patients undergoing IM therapy. A total of 86 CML patients on 
IM therapy (43 IM resistances and 43 IM responses) were included in this study. 
Using HRM analysis, 86 CML patients were screened for PDGFRA variants of exon 
10 (c.1432 T>C), exon 12 (c.1701 A>G), exon 14 (c.1977 C>A) and exon 18 (c.2525 
A>T). The selected samples with showing different melting curve profile from the 
reference genotype was subjected to DNA sequencing analysis to validate the 
genotype. From the data analysed, two PDGFRA variants were detected in exons 10 
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and 12. The established HRM profile has demonstrated 100% sensitivity and 
specificity when compared to DNA sequencing. PDGFRA exon 10 (c.1432 T>C) 
showed a significant risk factor (OR 3.797; 95% CI: 1.502 – 9.591; p = 0.005) for the 
development of IM resistance. PDGFRA exon 12 (c.1701 A>G) was not a significant 
risk factor (OR 1.597; 95% CI: 0.681 – 3.745; p = 0.281) for IM resistance. However 
there was no PDGFRA heterogeneity detected for both exon 14 c.1977 C>G and 
exon 18 c.2525 A>T. The results suggested that PDGFRA influenced IM resistance 
in CML patients and further analysis are warranted to confirm the role of PDGFRA 










1.1  Study overview 
Leukemia is defined as the uncontrolled proliferation or expansion of haematopoietic 
cells that do not retain the capacity to differentiate normally to mature white blood 
cells. In 2010, the incidence of leukemia was reported to be increased over the years 
from 30,800 cases in year 2000 to 44,790 in year 2009 worldwide and it was 
estimated that by 2018, 60,300 people diagnosed with leukemia in United States 
(Panno, 2005; Murphy et al., 2018). In Malaysia population, leukemia was reported 
to be the sixth most frequent cancer from 2007 to 2011, after lymphoma and cancer 
of nasopharynx, and it accounted for 4.4% of all types of cancer (Azizah et al., 
2016). 
According to World Health Organisation (WHO) leukemia is divided into two main 
classes according to their progression. It can be either acute leukemia or chronic 
leukemia. In acute leukemia, the abnormal blasts remain very immature and the 
number of blasts increases rapidly. While for chronic leukemia, the cells are more 
mature with presence of some blasts cells and will progress slowly and gradually 
than in acute leukemia. 
This leukemia can arise either of the two types of white blood cells – lymphoid cells 
or myeloid cells. Based on the cells affected, there are four types of leukemia; acute 
lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic 




Acute lymphocytic leukemia (ALL) is marked by neoplasia of precursor B- or 
precursor T-lymphoid cells in blood. It was reported to be the most common cancer 
among children with highest incidence among aged 1 to 10 years. In ALL, the 
accumulation of leukemic cell in the bone marrow and extramedullary site occur due 
to abnormal proliferation and differentiation of the leukemic cells which may lead to 
anemia, splenomegaly, hepatomegaly, lymphadenophaty and other manifestation of 
organ infiltration (Kebriaei et al., 2002). 
Acute myeloid leukemia (AML) is a type of leukemia that affects the myeloid cells. 
AML grows rapidly which is characterized by accumulation of immature blastic cells 
that proliferate abundantly with lack of normal differentiation (Mendelsohn et al., 
2008). 
Chronic lymphoid leukemia (CLL) is reported to be the most common form of 
leukemia in adults with more than 10,000 people diagnosed every year in the United 
State with approximately 75% of survival rate (Bozzone, 2009). CLL affects the 
lymphoid cells which progress slowly over times. 
In CML, the myeloid cells undergone uncontrolled expansion of mature and 
maturing granulocytic cells without loss their capacity to differentiate. The incidence 
were about 1 to 2 cases per 100,000 adults and classified as the most common 
chronic myeloproliferative disorder  (Jemal et al., 2010). CML commonly affect 
older patients with a median age of about 65 years and rarely diagnosed in children 
(Zhang and Rowley, 2011). In Malaysia, the occurance of CML in 2007 to 2011 was 
reported as 14.1% of all type of leukemia and 29.9% of myeloid leukemia (Azizah et 
al., 2016). Even though the incidence rate in Asian countries is lower compared to 
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Western counteries, the occurrence of CML in Asians tends to affect younger 
population with median age 36 years old (Au et al., 2009). 
CML is associated with the presence of the Philadelphia (Ph) chromosome and it was 
the first cancer that shows a consistent genetic abnormality (Sherbenou and Druker, 
2007). The presence of Ph chromosome has become a hallmark in CML 
identification. The Ph chromosome was first discovered by Nowell and Hungerford 
in 1960 and later Janet Rowley that characterized the Ph chromosome to be the 
results of reciprocal translocation between chromosome 9 and 22, t(9;22)(q34;q11).  
In early 1980s, with the enhancement of molecular biology has led to the discovery 
of human homologue of the murine Abelson1 gene (ABL1gene) which located on 
chromosome 9 was found to be translocated to the chromosome 22 in CML patients. 
Later in 1984, the breakpoint cluster region (BCR gene) on chromosome 22 was 
explored (Goldman and Mughal, 2008). The translocation has resulted in a BCR-
ABL fusion gene (Figure 1.1). this fusion gene  codes for BCR-ABL transcript and 
fusion protein with a constitutively active tyrosine kinase activity and increased 
activation of multiple signal transduction pathways (Kurzrock et al., 1988). These, 
later will leads to a massive production of myeloid cell that induce leukemia. The Ph 
chromosome has been observed in approximately 95% among CML patients (Faderl 
et al., 1999).  
The presence of well-defined pathogenetic of CML has led to the development of IM 
which is a tyrosine kinase inhibitor that inhibit both ABL and BCR-ABL protein. 
Since the BCR-ABL fusion protein is a constitutively activated tyrosine kinase that 
causes CML, IM has been one of the  treatment options in treating newly diagnosed 
patients or patient who have not respond to previous treatment  (Druker et al., 2001). 
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The clinical use of IM has resulted in significantly improve prognosis and survival 
rate where 80% to 90% of patients in early chronic phase have shown major 
cytogenetic responses toward IM (Buchdunger et al., 2001).  
In addition to BCR-ABL, IM also inhibits other tyrosine kinases of c-KIT and 
platelet derived growth factor alpha (PDGFRA). Platelet derived growth factor 
(PDGF) receptor is belong to the receptor tyrosine kinase family of type III group. 
The genetic alteration of this receptor was reported mostly in myeloproliferative 
disorder and solid tumor such as in myelomonocytic leukemia, gastrointestinal 
stromal tumors (GISTs) and gliomas (Arora and Scholar, 2005; Demoulin and 
Montano-Almendras, 2012). The discovery that IM also blocks PDGF receptor was a 
major breakthrough. Where, it  have shown to inhibit PDGFRA at the concentration 
similar to the inhibition concentration for BCR-ABL (Heinrich et al., 2000). In 
addition, several studies also showed a significant response of IM to the treatment of 
GIST patients which  involved the PDGFRA kinase (Druker, 2004).  
However, until today some patients in both CML and GIST has become resistant 
towards IM therapy. The emergence of resistance has prompted intense research on 
wider prospects of mechanism involve in IM resistant. Previous studies have showed 
that PDGFRA exon 10, 12, 14 and 18 were the most common site for PDGFRA 
mutation that associated with IM treatment response (Holtkamp et al., 2006). 
Therefore, this present study focused on application of High Resolution Melting 
(HRM) analysis in detection of PDGFRA variant in exon 10, 12, 14 and 18 and its 
association with IM resistant in CML patients. 
HRM analysis is gaining more demands upon today’s laboratories to generate a great 
need for rapid and cost-effective analytical methods. This technique was first 
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introduced in 2002 by a collaboration between academics at the University of Utah 
(UT,USA) and company Idaho Technology (UT,USA) (Montgomery et al., 2010). 
The flexibility of HRM analysis has allowed it to be applied in wide range of 
disciplines for a variety of applications including gene scanning, genotyping, 
sequence matching and also in methylation analysis (Erali et al., 2008). Perhaps, this 
technique would be able to discriminate even small sequence variations of single 












Figure 1.1 The reciprocal translocation of ABL1 gene on chromosome 9 into the 
BCR region on chromosome 22 that resulted in the formation of 











1.2 Chronic Myeloid Leukemia and clinical phases 
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease originating 
from an abnormal pluripotent bone marrow stem cell. The progression of CML is 
slow during their early phases (Goldman and Mughal, 2008). The disease is neither 
preventable nor inherited and the cause for its formation is unknown in majority of 
the patients (Quintás-Cardama and Cortes, 2006).   
CML consists of three phases based on clinical features and laboratory findings: the 
chronic phase (CP), the accelerated phase (AP) and the blast phase (BP) or blast 
crisis. Most cases of CML are diagnosed during the CP with a few clinical sign and 
symptoms that vary among individuals include fatigue, anemia, progressive 
splenomegaly and leucocytosis. CML patients at this phase usually have mild 
symptoms and usually asymptomatic. Approximately 90% of patients are diagnosed 
in the CP (Cortes et al., 2006). According to World Health Organization (WHO), CP 
is characterized by < 10% blasts in the blood which can last for several years. 
Without effective treatment, CML can progress to the AP or BP which usually 
associated with additional chromosomal and molecular alterations (Calabretta and 
Perrotti, 2004).   
In AP, patients may show a sign of 10 to 19% of blasts in peripheral blood, presence 
of ≥ 20% basophils, persistent thrombocytopenia and increasing spleen size 
(Baccarani et al., 2013). According to Cortes et al, in 2006, two-third of patients go 
through the AP before develop into the BP which is the terminal phase of CML. It is 
characterized by more than 20% of leukemic cells in blood with extramedullary 
involvement (Kantarjian et al., 1988; Baccarani et al., 2013). At this blast phase, 
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immature cells proliferate rapidly and progression of disease considerably fast within 
5 years of diagnosis. 
 
1.3 Diagnosis of CML 
CML is diagnosed by mean of haematological testing, cytogenetic analysis and 
molecular diagnosis. Complete blood count is the first indicator of CML diagnosis. 
The typical haematologic findings are anemia with haemoglobin level less than 7 
gm/dl to 11 gm/dl as well as marked leucocytosis with elevation of total leukocyte 
count from 100 to 500 x 10
9
/L. The peripheral blood smear demonstrated immature 
white cells of all stages including neutrophils, metamyelocytes, myelocytes, 
promyelocytes and blast cells.  The abnormal results in blood screening are followed 
with bone marrow aspirate analysis and trephine biopsy. The bone marrow aspirate 
usually shows a marked myeloid hyperplasia together with markedly increased of 
myeloid to erythroid precursor (M:E) ratio from 20:1 to 49:1 (Rodgers and Young, 
2013). 
The cytogenetics analysis is performed by mean of chromosome banding analysis 
(CBA) of marrow cell metaphases (Shaffer et al., 2013) to detect additional 
chromosomal abnormalities which determined by the presence of Ph chromosome.  
If marrow cells cannot be obtained, CBA can be replaced by interphase fluorescence 
in situ hybridization (I-FISH) using dual colour fusion probes that allow detection of 
BCR-ABL + nuclei to detect some variant translocation (Testoni et al., 2009).  
More recently, molecular diagnostic methods including FISH and quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) have been introduced 
9 
 
and were reported to be more sensitive than conventional cytogenetic analysis for the 
detection of BCR-ABL positive cells. The qRT-PCR analysis identifies the transcript 
types of either e14a2 or 13a2 (also known as b3a2 and b2a2) and rarely recognizes 
the transcript of e19a2 or e1a2 which indicate the BCR-ABL protein weight 
(Baccarani et al., 2012). 
 
1.4 Treatment and management 
Treatment of the CML in last century was based on radiotherapy, busulfan, and 
hydroxyurea (Pavlovsky et al., 2009). Those treatments were able to control the 
clinical manifestation of the disease, but rarely of capable to supress the progression 
of the disease. Following this, interferon-alpha and allogenic stem cell 
transplantation was introduced and showed to induce cytogenetic response among 
the patients (Goldman, 2009; Pavlovsky et al., 2009).  
Increase understanding on the molecular pathogenesis of CML and discovery of the 
Philadelphia chromosome has led to the development of IM; the tyrosine kinase 
inhibitor (TKI) that target the BCR-ABL protein (Pavlovsky et al., 2009). Since then, 
IM has become a gold standard treatment that results in dramatically improved 
clinical management and outcome in CML patients (Manley et al., 2002). 
 
1.5 Imatinib mesylate 
Imatinib mesylate also known as Gleevec or formely referred as STI571 (Norvatis, 
Switzerland), is a specific inhibitor of tyrosine kinases BCR-ABL and platelet- 
derived growth factor (PDGF) and stem cell factor (Savage and Antman, 2002). IM 
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was designated chemically as 4-[[(4-methyl-1-1piperazinyl)methyl]-N-[4-methyl-3-
[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl] benzamide nethanesulfonate with a 
molecular formula of C29H31N7O.CH4SO3 and relative molecular mass of 589.7 
(Cohen et al., 2002). IM has been approved by the Food and Drug Administration 
(FDA) for treatment of CML and gastrointestinal stromal tumors (GISTs) (Savage 
and Antman, 2002; O'brien et al., 2003). The initial standard doses of IM for a newly 
diagnosed Ph+ CML patients is 400 mg daily and 600 mg daily for CML patients in 
the accelerated and blasts phases (Talpaz et al., 2002; Druker, 2004; Pavlovsky et al., 
2009). Figure 1.2 shows the chemical structure of IM.   
Administration of IM to CML patients has resulted in marked clinical response. An 
in vitro and in vivo study, has shown the ability of IM to inhibit proliferation of cells 
expressing BCR-ABL and have reduced the formation of the BCR-ABL positive 
colonies by 95% (Buchdunger et al., 2001; Savage and Antman, 2002). About 65% 
to 90% CML patient who have failed interferon-α and 80% to 90% of untreated 
CML patients have showed to induce complete cytogenetic response (CCyR) from 
the IM treatment which demonstrated by the complete absence of Ph chromosome in 
CML cell metaphases (Druker et al., 2001; Kantarjian et al., 2002). IM therapy 
specifically inhibit proliferating myeloid cell with minimal side effects including 
neutropenia, thrombocytopenic anemia and non-hematologic adverse effects 
including nausea, skin rash, peripheral edema and muscle cramps which only can be 






Figure 1.2 Chemical structure of IM (Adapted from (Manley et al., 2002)).  
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1.5.1 Mechanism of action 
IM was developed as a specific inhibitor of the BCR-ABL protein tyrosine kinase. 
IM exhibits potent inhibitory activity against ABL kinase and the chimeric BCR-
ABL fusion oncoprotein, KIT, and PDGFR (Quek and George, 2010).  
At the cellular level, IM binds to the inactive form of ABL kinase and function as a 
competitive inhibitor of the adenosine triphosphate (ATP) binding site of the BCR-
ABL protein. The main purpose of the IM binding is to block the 
autophosphorylation of the ABL kinase, which responsible for kinase activation and 
signal transduction (Buchdunger et al., 2002). In BCR-ABL expressing cells, IM has 
shown to produce three related effects; inhibition of BCR-ABL autophosphorylation, 
inhibition of proliferation and induction of apoptosis (Druker et al., 1996; 
Gambacorti-Passerini et al., 1997).  
The BCR-ABL protein targets were reported to include members of Ras, 
Phosphatidylinositol-3 kinase (PI3K)/Akt and Jak/Stat signalling pathway that play a 
role in regulating cell proliferation and apoptosis. BCR-ABL also act by repealing 
the cell dependence on external growth factors by up-regulating the production of 
interleukin-3 as well as altering the cell adhesion properties by expression and 
activation of the focal adhesion kinase and associated proteins. Therefore, IM 
prevented the BCR-ABL tyrosine kinase enzyme from phosphorylating subsequent 
proteins and initiating the signalling cascade (Kantarjian et al., 2006). The schematic 






Figure 1.3 Schematic diagrams on mechanism of action of IM. (A) Activation of 
BCR-ABL that led to autophosphorylation of ABL kinase (B) Binding  
of IM to the BCR-ABL that block the autophosphorylation of ABL 










1.6 IM resistance 
The responses toward IM treatment are assessed based on three types of response, 
which are the haematological response, cytogenetic response and molecular 
response. These responses were assessed on the third month of continuous IM 
treatment followed by sixth month, twelfth month and each subsequent three months 
later. According to LeukemiaNet 2013 recommendation (Table 1.1), IM response 
groups were divided into three major groups, which are the optimal, warning and 
failure. The response criteria were mostly based on the molecular response. 
However, some CML patients has experience an unsatisfactory therapeutic effects 
with IM. The main reason is because of the development of resistance to IM. The 
resistance to IM can be divided into primary resistance and secondary resistance. 
Where, both groups have led to less favourable prognosis to CML patients.   
The primary resistance or also known as intrinsic resistance is defined as having less 
than complete cytogenetic response within 12 months after IM treatment initiation 
and/or having more than 1% of BCR-ABL1 transcript when tested with (RT-qPCR) 
(Baccarani et al., 2013).  
While, secondary resistance which known as acquired resistance was characterized 
by loss of complete haematological response, complete cytogenetic response, loss of 
major molecular response confirm with two constitutive test to show the presence of 
BCR-ABL1 transcripts level of more or equal to 1% and may presented with 
mutations and/or clonal chromosome abnormalities (Baccarani et al., 2013) 
Approximately about 33% of CML patients treated with IM do not achieve complete 
cytogenetic response (CCyR) (Bixby and Talpaz, 2009; Hochhaus et al., 2009). The 
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mechanisms of resistance to IM have been extensively studied and can be divided 




















Table 1.1 Definition of response to tyrosine kinase inhibitor as first line 
treatment in LeukemiaNet 2013 recommendation. 
Time  Optimal response Warning  Failure 






BCR-ABL1 ≤ 10% 
and/or 
Ph+ ≤  35% (PCyR) 





Ph+ > 95% 
6 
months 
BCR-ABL1 < 1% 
 and/or  
Ph+ 0% (CCyR) 
BCR-ABL1 1-10%  
and/or  
Ph+ 1-35% 
BCR-ABL1 > 10%  
and/or  
Ph+ > 35% 
12 
months 
BCR-ABL1 ≤  0.1% 
(MMR) 
BCR-ABL1 0.1-1% BCR-ABL1 > 1%  
and/or  




MMR or better CCA/Ph- (-7 or 7q-) Loss of CHR 
Loss of CCyR 
Loss of MMR* 
Mutations 
CCA/Ph+ 
N/A: Not available; MMR: BCR-ABL1 ≤0.1%=MR or better; CCA/Ph+: Clonal chromosomal 
abnormalities in Ph+ cells; CCA/Ph-: Clonal chromosomal abnormalities in Ph- cells; *: in 2 




1.6.1 BCR-ABL dependent 
There are two main mechanisms involved under the BCR-ABL dependent which are 
amplification of BCR-ABL gene and point mutation in the tyrosine kinase domain of 
the ABL gene (Gambacorti-Passerini et al., 2003).   
The amplification of BCR-ABL gene in IM resistant leukemic cells was first 
described in a LAMA84R cell line generated by culturing cells with increasing IM 
concentrations where it express about five times more BCR-ABL protein compared 
to the parent LAMA84 cells. Further analysis using marker chromosome labelled by 
BCR-ABL specific probe confirmed that the overexpression of the protein was 
because of the amplification of the BCR-ABL gene (le Coutre et al., 2000). While, 
the fluorescence in situ hybridization (FISH) of CML blast phase patients following 
treatment with IM discovered the same finding of BCR-ABL amplification (Melo and 
Chuah, 2007). 
As IM was a competitive inhibitor of the ATP binding site of ABL, mutations 
affecting IM binding were likely to produce non-functioning enzymes. However, 
later studies showed that IM binds and stabilise ABL in its inactive conformation 
where no ATP binds to the kinase rather than competing with ATP for binding. 
Consequently, mutations in the kinase domain of BCR-ABL may be able to disrupt 
IM binding without interfering its enzymatic activity (Tauchi and Ohyashiki, 2004). 
Investigation of mechanism of IM resistance then has led to the discovery of T315I 
mutation in the ABL kinase domain of BCR-ABL that confers resistant toward IM via 
blocking IM binding to ABL where has subsequently been found in at least one 
BCR-ABL positive cell (Gorre et al., 2001; Ricci et al., 2002).   
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1.6.2 BCR-ABL independent  
BCR-ABL independent mechanism mainly involves several factors and can be due to 
alterations in their pharmacokinetics for example drug efflux/influx and binding of 
IM in the plasma by α-1 acid glycoprotein. Overexpression of adenosine triphosphate 
binding cascade (ABC) transporter in the cell of blast phase CML patients has been 
linked to the development of IM resistance. This ABC transporter is a 
transmembrane protein that regulate efflux of numerous chemotherapeutic agents 
(Mahon et al., 2000). Whereas, influx inhibition through human organic cation 
transporter (hOCT1) was also an important factor that affecting regulation 
intracellular IM and any polymorphism in these transporter have the ability to alter 
the entry of IM into the cell which may contribute to development of resistance 
(Crossman et al., 2005; Quintas-Cardama and Cortes, 2009). 
When leukemic cells from patients were analysed after initial treatment with IM, 
only partial inhibition was observed although BCR-ABL could completely blocked 
when exposed to the equivalent plasma IM concentrations (Druker et al., 2001; 
Gambacorti-Passerini et al., 2002). These can be explained that approximately 95% 
of IM is bound to the plasma protein which is α-1-acid glycoprotein (AGP) and 
albumin. The binding of AGP can inhibit the activity of IM (Gambacorti-Passerini et 
al., 2000; Larghero et al., 2001; Le Coutre et al., 2002). Therefore, IM that present in 
the plasma could be mostly bound to the AGP and thus biologically inactive.  
The resistance that involving BCR-ABL independent is not only due to the 
mechanism mentioned above. Several studies had reported that a significant portion 
of IM resistance in CML patients could not be associated with BCR-ABL fusion 
gene. Therefore it is presumed that the mechanism of IM resistance in such patients 
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might be via additional mechanisms involving other IM targeted tyrosine kinases for 





Figure 1.4 Mechanisms of resistance against IM. (1) Mutation in the BCR-ABL  
gene (2) Amplification of BCR-ABL (3) Drug influx/efflux 
mechanisms (4) Autocrine cytokine secretion (5) Activation of 
alternative signalling pathway (6) Wnt/β-catenin pathway (7) low 





1.7 Tyrosine kinase  
Tyrosine kinases are enzymes that catalyse the transfer of the gamma (ϒ) phosphate 
group from adenosine triphosphate to target protein. It plays a role in diverse 
regulatory processes including the modulation of growth factor signalling, 
proliferation and differentiation. Tyrosine kinases can be classified into receptor 
protein kinase and non-receptor protein kinase. There are approximately 60 RTKs 
that have been identified and further divided into 20 subfamilies (Pawson, 2002)  
The receptor tyrosine kinase are activated by ligand binding which then induce 
dimerization of these receptor resulting in autophosphorylation of their cytoplasmic 
domain and activation of the tyrosine kinase activity (Paul and Mukhopadhyay, 
2004). The most important downstream signalling pathways activated by receptor 
tyrosine kinase including the Ras/Raf mitogen-activated protein kinase pathway, the 
phosphoinositol 3’-kinase/AKT pathway, the signal transducer and activator of 
transcription 3 pathway (JAK/STAT),  the protein kinase C pathway and scaffolding 
protein (Schlessinger, 2000). These intracellular mediators then effects the biological 
processes including cell growth, migration, differentiation and death (Blume-Jensen 
and Hunter, 2001). 
Even there are multiple levels of regulation of tyrosine kinase, dysregulation may 
also occur which lead to malignancy through several mechanisms including 
amplification of receptor tyrosine kinase gene, genetic alterations and autocrine-
paracrine stimulation through aberrant growth factor loops (Zwick et al., 2002). In 
CML, the related tyrosine kinase involve is the ABL gene which classified under non 
receptor tyrosine kinase. However in this study we are exploring others tyrosine 
kinase which is PDGFRA that classified under type III receptor tyrosine kinase, since 
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the receptor in this class is one of the intriguing receptor tyrosine kinase in terms of 
evolutionary, functional and clinical considerations (Grassot et al., 2006; Verstraete 
and Savvides, 2012). 
 
1.7.1 Platelet-derived growth factor receptor alpha (PDGFRA) 
Platelet derived growth factor receptor (PDGFR) or also known as CD140A and 
PDGFR2 is belongs to the class III of tyrosine kinases have shown to play a role in 
mesenchymal cell migration and proliferation (Jones and Cross, 2004). These growth 
factors are mitogens for the cells of mesenchymal origin. Two type of PDGFRs have 
been identified which are alpha type (PDGFRA) and beta type (PDGFRB). These 
two types of subunit are differently expressed on the cell surface of different cell 
types.  
The full length PDGFRA is encoded by a 6.4 kb transcript generated from a 
promoter upstream of exon 1 (P1 promoter). It is located at chromosome 4 in the 
4q12 and has 23 exons and 1089 amino acid residues (Mosselman et al., 1996). The 
structure of PDGFRA receptor comprises an extracellular domain with five 
immunoglobulin (Ig), a juxtamembrane domain inside the cell membrane and two 
cytoplasmic tyrosine kinase domain (Figure 1.5) (Claesson-Welsh et al., 1989; 
Matsui et al., 1989). PDGFRA bind to its ligand (PDGF-A, -B, -C and –D) and 
induce receptor dimerization that lead to autophosphorylation of their cytoplasmic 
tyrosine residue thus activate inter/intracellular kinase activity, initiating the 





Figure 1.5 Schematic diagram of PDGFRA structure (Adapted from 













Tyrosine kinase domain 
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1.7.2 PDGFRA and IM resistance 
In addition to BCR-ABL, IM is also a potent inhibitor for c-KIT and PDGFRA in 
gastrointestinal stromal tumour (GISTs), and also has shown marked response as a 
treatment in glioblastoma, dermatofibrosarcoma protuberans, malignant peripheral 
nerve sheet tumour (MPNST) and chronic myelomonocytic leukemia (Buchdunger et 
al., 2002). Several clinical trials have demonstrated a significant response to IM in 
advanced GISTs patients and have shown to inhibit the PDGFRA tyrosine kinase at 
the concentration similar to the concentration required for the inhibition of BCR-ABL 
in CML (Heinrich et al., 2003a).  
Mutations of PDGFRA lead to ligand-independent activation of the receptor.  
Approximately about 80% of GISTs patients expressed the mutated KIT receptor. 
However about 8% of the patients had a normal KIT and 5% of the patients 
demonstrated to have mutation in the PDGFRA receptor (Joensuu, 2006). Since, 
PDGFRA is very similar to the KIT and found in close proximity on chromosome 
4q12, the mutation of the receptor seen to be related (Spritz et al., 1994). 
Most of the PDGFRA mutations occur in exons 10, 12, 14, 18 in GISTs and MPNT. 
The site of mutations may influence response to tyrosine kinase inhibitors such as IM 
(Holtkamp et al., 2006).  Mutation in exon 18 of PDGFRA (D842V) has shown to be 
resistant toward IM therapy which account for about 89.6% of cases in GISTs 
(Corless et al., 2005). It is suggested that a similar mutational status of PDGFRA 
might also occur in CML patients that causes development of resistance towards IM 
treatment. 
 
